Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：24

作者：

Koerkamp, B. Groot ^{[1
]}

Janssen, Q. P. ^{[1
]}

van Dam, J. L. ^{[1
]}

Bonsing, B. A. ^{[2
]}

Bos, H. ^{[3
]}

Bosscha, K. P. ^{[4
]}

Haberkorn, B. C. M. ^{[5
]}

de Hingh, I. H. J. T. ^{[6
]}

Karsten, T. M. ^{[7
]}

Van der Kolk, M. B. ^{[8
]}

Liem, M. S. L. ^{[9
]}

Loosveld, O. J. L. ^{[10
]}

Patijn, G. A. ^{[11
]}

van Santvoort, H. C. M. ^{[12
]}

de Vos-Geelen, J. ^{[13
]}

van der Holt, B. ^{[14
]}

Homs, M. Y. V. ^{[15
]}

van Tienhoven, G. ^{[16
]}

Besselink, M. G. ^{[17
]}

Wilmink, H. W. ^{[18
]}

机构：

[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands

[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands

[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands

[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands

[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands

[6] Catharina Hosp, Surg, Eindhoven, Netherlands

[7] OLVG Hosp, Surg, Amsterdam, Netherlands

[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands

[9] Med Spectrum Twente, Surg, Enschede, Netherlands

[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands

[11] Isala Hosp, Surg, Zwolle, Netherlands

[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands

[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands

[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands

[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands

[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands

[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands

[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA83

引用

页码：S1323 / S1323

页数：1

共 50 条

[21] Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy
Pierluigi di Sebastiano
Tommaso Grottola
F. Francesco di Mola
Updates in Surgery, 2016, 68 : 235 - 239
[22] Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)
van Dongen, Jelle C.
Suker, Mustafa
Versteijne, Eva
Bonsing, Bert A.
Mieog, J. Sven D.
de Vos-Geelen, Judith
van der Harst, Erwin
Patijn, Gijs A.
de Hingh, Ignace H.
Festen, Sebastiaan
Ten Tije, Albert J.
Busch, Olivier R.
Besselink, Marc G.
van Tienhoven, Geertjan
Koerkamp, Bas Groot
van Eijck, Casper H. J.
ANNALS OF SURGERY, 2022, 275 (05) : 979 - 984
[23] A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
Daniel H. Palmer
Deborah D. Stocken
Helen Hewitt
Catherine E. Markham
A. Bassim Hassan
Philip J. Johnson
John A. C. Buckels
Simon R. Bramhall
Annals of Surgical Oncology, 2007, 14 : 2088 - 2096
[24] Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer : Meta-analysis and trial sequential analysis of randomized controlled trials
Hajibandeh, Shahab
Hajibandeh, Shahin
Intrator, Christina
Hassan, Karim
Sehmbhi, Mantej
Shah, Jigar
Mazumdar, Eshan
Kausar, Ambareen
Satyadas, Thomas
ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2023, 27 (01) : 28 - 39
[25] Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience
Son, Chang O.
Pai, Sachin Gopalkrishn
Satti, Suma
Dornelles, Adriana
Bolton, John S.
Conway, W. Charles
Fuloria, Jyotsna
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[26] Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
Neibart, Shane S.
Mamidanna, Swati
Chundury, Anupama
Sayan, Mutlay
Alexander, H. Richard
August, David A.
Berim, Lyudmyla D.
Boland, Patrick M.
Grandhi, Miral S.
Gulhati, Prateek
Hochster, Howard S.
Langan, Russell C.
Spencer, Kristen R.
Kennedy, Timothy J.
Deek, Matthew P.
Jabbour, Salma K.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (06) : 2557 - +
[27] Clinical Outcomes of the Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine Versus FOLFIRINOX
Choi, Y. J.
Kang, J. S.
Byun, Y.
Kim, H. S.
Han, Y.
Kim, H.
Kim, E.
Kwon, W.
Jang, J. Y.
PANCREAS, 2019, 48 (10) : 1414 - 1414
[28] Efficacy of Neoadjuvant Chemotherapy Using Gemcitabine and S-1 for Resectable and Borderline Resectable Pancreatic Cancer
Aoki, T.
Mori, S.
Sakuraoka, Y.
Suzuki, T.
Nishi, Y.
Arakawa, T.
Shimizu, T.
Tago, K.
Park, K. H.
Harada, N.
Shiraki, T.
Iso, Y.
Kubota, K.
PANCREAS, 2019, 48 (10) : 1404 - 1404
[29] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
Hozaeel, Wael
Pauligk, Claudia
Homann, Nils
Luley, Kim
Kraus, Thomas Werner
Trojan, Jorg
Bechstein, Wolf O.
Grimm, Kersten
Heise, Bettina
Schmiegel, Wolff
Pink, Daniel
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[30] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial
Thorsten O. Goetze
Alexander Reichart
Ulli S. Bankstahl
Claudia Pauligk
Maria Loose
Thomas W. Kraus
Moustafa Elshafei
Wolf O. Bechstein
Jörg Trojan
Matthias Behrend
Nils Homann
Marino Venerito
Wolfram Bohle
Michael Varvenne
Claus Bolling
Dirk M. Behringer
Karsten Kratz-Albers
Gabriele M. Siegler
Wael Hozaeel
Salah-Eddin Al-Batran
Annals of Surgical Oncology, 2024, 31 : 4121 - 4122

← 1 2 3 4 5 →